Literature DB >> 24739542

Use of ambulatory blood pressure measurement in the definition of resistant hypertension: a review of the evidence.

Alexandre Persu1, Eoin O'Brien2, Paolo Verdecchia3.   

Abstract

Resistant hypertension as defined by the European Society of Hypertension and American Heart Association is a blood pressure that remains uncontrolled despite concomitant intake of at least three antihypertensive drugs (one of them preferably being a diuretic) at full doses. This definition is still based on office rather than out-of-office blood pressure measurement. In this review we propose a new, stricter definition of resistant hypertension based on ambulatory blood pressure measurement. The main arguments in favor of this are: (1) in patients with resistant hypertension, ambulatory blood pressure is an independent predictor of cardiovascular morbidity whereas, after adjustment for conventional risk factors, conventional blood pressure has little added value; (2) white-coat resistant hypertension (uncontrolled office with normal ambulatory blood pressure) is frequent (30-40% of patients with apparently resistant hypertension) carrying a prognosis similar to that of controlled hypertension, and intensification of blood pressure lowering treatment, or the use of nondrug treatment strategies such as renal denervation or carotid baroreceptor stimulation, is not justified; (3) masked resistant hypertension (controlled office with elevated ambulatory blood pressure) is frequent (approximately one-third of patients with controlled office blood pressure on triple antihypertensive therapy) and associated with an increased risk of cardiovascular events; in such patients, treatment intensification should be considered; (4) the current definition of resistant hypertension (office blood pressure ⩾ 140/90 mm Hg on triple antihypertensive therapy) allows a substantial proportion of patients with spurious or white-coat resistant hypertension to undergo renal denervation in the absence of proven long-term benefits.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24739542     DOI: 10.1038/hr.2014.83

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  13 in total

1.  What is the benefit of renal denervation?

Authors:  Takuya Kishi
Journal:  Hypertens Res       Date:  2016-01-14       Impact factor: 3.872

Review 2.  Renal Artery Stenosis in Patients with Resistant Hypertension: Stent It or Not?

Authors:  Patricia Van der Niepen; Patrick Rossignol; Jean-Philippe Lengelé; Elena Berra; Pantelis Sarafidis; Alexandre Persu
Journal:  Curr Hypertens Rep       Date:  2017-01       Impact factor: 5.369

Review 3.  The Use of Precision Medicine to Manage Obstructive Sleep Apnea Treatment in Patients with Resistant Hypertension: Current Evidence and Future Directions.

Authors:  Esther Sapiña; Gerard Torres; Ferran Barbé; Manuel Sánchez-de-la-Torre
Journal:  Curr Hypertens Rep       Date:  2018-06-08       Impact factor: 5.369

4.  The measurement of orthostatic blood pressure as a screening tool for masked hypertension with abnormal circadian blood pressure rhythm.

Authors:  Takahiro Komori; Kazuo Eguchi; Kazuomi Kario
Journal:  Hypertens Res       Date:  2016-06-16       Impact factor: 3.872

Review 5.  Renal Denervation After Symplicity HTN-3 - Back to Basics. Review of the Evidence.

Authors:  Alexandre Persu; Fadl Elmula M Fadl Elmula; Yu Jin; Ingrid Os; Sverre E Kjeldsen; Jan A Staessen
Journal:  Eur Cardiol       Date:  2014-12

Review 6.  Resistant Hypertension: A Real Entity Requiring Special Treatment?

Authors:  Stefano Taddei; Rosa Maria Bruno
Journal:  Eur Cardiol       Date:  2016-08

Review 7.  Prognostic Importance of Ambulatory Blood Pressure Monitoring in Resistant Hypertension: Is It All that Matters?

Authors:  Claudia R L Cardoso; Gil F Salles
Journal:  Curr Hypertens Rep       Date:  2016-12       Impact factor: 5.369

Review 8.  Renal Denervation for Treatment of Hypertension: a Second Start and New Challenges.

Authors:  Alexandre Persu; Sverre Kjeldsen; Jan A Staessen; Michel Azizi
Journal:  Curr Hypertens Rep       Date:  2016-01       Impact factor: 5.369

9.  Renal denervation therapy for resistant hypertension.

Authors:  Mark Davis; Ernesto L Schiffrin; Dominique Joyal
Journal:  Curr Treat Options Cardiovasc Med       Date:  2014-12

10.  Factors associated with the changes from a resistant to a refractory phenotype in hypertensive patients: a Pragmatic Longitudinal Study.

Authors:  Cristina Navarro-Soriano; Miguel-Angel Martínez-García; Gerard Torres; Ferrán Barbé; Candela Caballero-Eraso; Patricia Lloberes; Trinidad Diaz Cambriles; María Somoza; Juan F Masa; Mónica González; Eva Mañas; Mónica de la Peña; Francisco García-Río; Josep María Montserrat; Alfonso Muriel; Grace Oscullo; Laura Feced Olmos; Alberto García-Ortega; David Calhoun; Francisco Campos-Rodriguez
Journal:  Hypertens Res       Date:  2019-06-17       Impact factor: 3.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.